Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Exudative Age-related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00536016
What this trial is testing

Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

Who this might be right for
Macular Degeneration
Jerini Ophthalmic 36
Large-scale testing (Phase 3)Active Not RecruitingNCT05904028
What this trial is testing

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research 603
Not applicableEnded earlyNCT04935411
What this trial is testing

Russian Registry of Patients With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 2,665
Post-approval studies (Phase 4)Study completedNCT02257632
What this trial is testing

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis Pharmaceuticals 41
Large-scale testing (Phase 3)Looking for participantsNCT03683251
What this trial is testing

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Who this might be right for
Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01624636
What this trial is testing

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 1
Large-scale testing (Phase 3)Study completedNCT00321997
What this trial is testing

A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Who this might be right for
Age-Related Macular Degeneration
Eyetech Pharmaceuticals 540
Early research (Phase 1)Active Not RecruitingNCT01736059
What this trial is testing

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

Who this might be right for
Non-exudative Age-related Macular DegenerationDiabetic RetinopathyRetina Vein Occlusion+2 more
University of California, Davis 15
Testing effectiveness (Phase 2)Study completedNCT03345082
What this trial is testing

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 366
Large-scale testing (Phase 3)Active Not RecruitingNCT06491914
What this trial is testing

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Who this might be right for
Neovascular Age-Related Macular DegenerationDiabetic Macular Edema
Regeneron Pharmaceuticals 1,126
Not applicableStudy completedNCT07235527
What this trial is testing

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Who this might be right for
Age Related Macular DegenerationExudative Age-Related Macular DegenerationAnti Vascular Endothelial Growth Factor
Saglik Bilimleri Universitesi 54
Testing effectiveness (Phase 2)Study completedNCT00373659
What this trial is testing

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
University of Miami 40
Not applicableStudy completedNCT00656903
What this trial is testing

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
National Eye Institute (NEI) 75
Testing effectiveness (Phase 2)Study completedNCT04820452
What this trial is testing

IBI302 in Patients With nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Innovent Biologics (Suzhou) Co. Ltd. 231
Early research (Phase 1)Study completedNCT02022540
What this trial is testing

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Who this might be right for
Age-Related Macular Degeneration (AMD)
PanOptica, Inc. 50
Large-scale testing (Phase 3)Study completedNCT01782989
What this trial is testing

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

Who this might be right for
Geographic Atrophy
Paul Yates, MD, PhD 286
Post-approval studies (Phase 4)Study completedNCT02581891
What this trial is testing

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Who this might be right for
Macular Degeneration
Bayer 287
Not applicableStudy completedNCT01840683
What this trial is testing

HELP Therapy for Dry AMD

Who this might be right for
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
B.Braun Avitum AG 22
Not applicableStudy completedNCT02304068
What this trial is testing

The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity

Who this might be right for
Acute Macular Degeneration
The Leeds Teaching Hospitals NHS Trust
Testing effectiveness (Phase 2)Study completedNCT05275205
What this trial is testing

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Who this might be right for
Neovascular Age-related Macular Degeneration
Unity Biotechnology, Inc. 51
Next Page